Mayer Brown and Latham & Watkins are advising on the $2.6 billion acquisition by Nestlé SA, the Swiss-based international food giant, of Aimmune Therapeutics, a U.S.-based specialist in treatments for food allergies.
Aimmune, based in Brisbane, California, has developed the drug Palforzia, the first and only Food and Drug Administration-approved treatment to help reduce the severity of the allergic reaction to peanuts in children aged 4 through 17.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
